MedTrace Logo

Treatment of ARDS With Instilled T3

NCT04115514 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-04-07

No results posted yet for this study

Summary

It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).

Conditions

  • ARDS, Human
  • Lung, Wet
  • Thyroid
  • Pulmonary Edema
  • Lung Inflammation

Interventions

DRUG

Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.

Study Drug Administration: * Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL * Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first. * Method: Instilled via a catheter through the ETT directly into the airway.

OTHER

Non-intervention

Standard of Care (SOC)

Sponsors & Collaborators

Principal Investigators

  • Timothy P Rich, MD · University of Minnesota

  • David H Ingbar, MD · University of Minnesota

  • Ronald A Reikoff, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04115514 on ClinicalTrials.gov